Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy (NASDAQ:GMAB)

Genmab is expanding beyond royalties with strong drug sales, a deep oncology pipeline, and $2.9B in cash, supporting long-term growth. Learn why GMAB stock is a buy.